Results for tag: "Arthritis Monoclonal Antibodies"

In the biotechnology industry, the Arthritis Monoclonal Antibodies market represents a specialized segment focused on utilizing monoclonal antibodies (mAbs) to treat various forms of arthritis, such as rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. Monoclonal antibodies are lab-engineered proteins that can bind to specific antigens, such as those involved in the inflammatory processes that characterize arthritis. The development of mAbs has been propelled by advancements in genetic engineering, protein engineering, and a deeper understanding of immunological mechanisms underlying joint inflammation and damage. These therapies aim to offer targeted intervention by either neutralizing inflammatory cytokines, modulating immune cell activity, or blocking specific receptors involved in the autoimmune response. The market includes several mAbs that have been approved for use and are considered valuable tools in the management of arthritis, providing relief for patients and the potential to slow disease progression. Ongoing research continues to explore novel targets for mAbs, aiming to enhance efficacy and reduce side effects compared to traditional treatments. Some prominent companies involved in the Arthritis Monoclonal Antibodies market include Amgen, which developed the widely used drug Etanercept; AbbVie, known for Adalimumab; Johnson & Johnson, maker of Golimumab; Roche, with its product Tocilizumab; and UCB, which markets Certolizumab Pegol. These companies are part of a competitive landscape where continuous innovation is imperative Show Less Read more